Physician profile
John Christopher Riedinger
NPI 1205283546
$1,812.35
in general payments reported to CMS, 2019-2025
33 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.96 · 2022: $214 · 2023: $206 · 2024: $458 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.04 | 2022-2025 | |
| Biogen, INC. | $134.77 | 2022-2025 | Vumerity |
| Novartis Pharmaceuticals Corporation | $105.70 | 2022-2025 | |
| Celgene Corporation | $105.08 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $104.28 | 2023-2025 | Strensiq, Ultomiris |
| Pfizer INC. | $88.20 | 2023-2025 | |
| Lundbeck LLC | $75.04 | 2024-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $60.83 | 2024-2025 | Wainua, Fasenra |
| Argenx US, INC. | $53.08 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Grifols USA, LLC | $39.24 | 2024 | Gamunex-C |
| Boston Scientific Corporation | $38.67 | 2024 | |
| Mallinckrodt Hospital Products INC. | $35.78 | 2024-2025 | Acthar |
| Acadia Pharmaceuticals INC | $35.03 | 2023-2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $34.85 | 2025 | Rexulti |
| Janssen Biotech, INC. | $34.36 | 2024-2025 | Tremfya |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $34.22 | 2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $32.15 | 2024 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $32.05 | 2024-2025 | Rystiggo, Zilbrysq |
| Takeda Pharmaceuticals U.S.A., INC. | $31.73 | 2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $30.95 | 2025 | Xeomin |
| Sandoz INC. | $28.54 | 2025 | Hyrimoz |
| Piramal Critical Care | $28.29 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.84 | 2022 | |
| Genzyme Corporation | $24.90 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.14 | 2024 | Crysvita |
| Catalyst Pharmaceuticals, INC. | $23.00 | 2022 | |
| Tg Therapeutics, INC. | $21.78 | 2024 | |
| Springworks Therapeutics, INC. | $19.26 | 2025 | Gomekli |
| Eisai INC. | $18.30 | 2025 | |
| Ionis Pharmaceuticals, INC. | $17.91 | 2025 | Dawnzera |
| Tanabe Pharma America, INC. | $17.49 | 2024 | |
| Aurinia Pharma U.S., INC. | $15.77 | 2025 | Lupkynis |
| Allergan, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Riedinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.